The dermatophytic onychomycosis treatment market size was valued at USD 4.3 Billion in 2022 and is projected to grow from USD 4.6 Billion in 2023 to USD 8.5 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.90% during the forecast period (2023 - 2032).

Onychomycosis is a fungal condition that affects the fingernails and toenails and can be painful, ugly, and persistent. Among the different types of onychomycosis are proximal subungual, white superficial, and distal subungual. This nail infection, which is caused by a range of microorganisms including dermatophytes, yeasts, and non-dermatophyte molds, is usually contracted by athletes foot sufferers. Onychomycosis symptoms include distorted nail shapes, a disagreeable smell, pale to yellow-brown discoloration, and crumbly, ragged, and brittle nail textures. Nail samples and clippings are typically cultured, and potassium, oxygen, and hydrogen (KOH) assays are utilized to determine the diagnosis. It can be treated with medicine, photodynamic treatments, laser therapy, and other methods

The prevalence of onychomycosis is one of the key factors driving the market's growth. Onychomycosis infections of the toenails occur far more frequently than those of the fingernails. The increased prevalence of dermatophyte-caused nail fungal infections and a sharp increase in prescriptions are expected to drive the market. According to a press release from Moberg Pharma AB, 35–40 million Americans have nail fungus, making up around 10% of the global population. This is likely to increase demand for the market for treating dermatophytic onychomycosis during the anticipated period.

Key Players

MRFR recognizes the following companies as the key players in the global dermatophytic onychomycosis treatment market—Bausch Health Companies Inc., Pfizer Inc., Galderma, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Cipla Inc., Kaken pharmaceuticals Co., Ltd., Other Players.

Segment Analysis

The global dermatophytic onychomycosis treatment market has been segmented based product type, route of administration, type, and distribution channel.

On the basis of product type, the market is segmented into tablets, nail paints. The nail paints segment was attributed to holding the largest market share in 2022.

Based on route of administration, the global dermatophytic onychomycosis treatment market has been segmented into oral, topical. The topical segment was expected to hold the largest market share in 2022.

On the basis of type, the market is segmented into prescribed, over-the-counter (OTC). The over-the-counter (OTC) segment was attributed to holding the largest market share in 2022.

Based on distribution channel, the global Dermatophytic onychomycosis treatment market has been segmented into hospitals & clinics, retail pharmacies, and online channels. The online channels segment was expected to hold the largest market share in 2022.

Regional Analysis

The global dermatophytic onychomycosis treatment market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe dermatophytic onychomycosis treatment market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The dermatophytic onychomycosis treatment market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World dermatophytic onychomycosis treatment market comprises of Middle East, Africa, and Latin America.

The largest market share for dermatophytic onychomycosis treatment was maintained by the North American regional sector. In 2022, the market in North America for treatments for dermatophytic onychomycosis was estimated to be worth USD 1.9 Billion. The increase in onychomycosis prescriptions, increased research, and rising demand for Jublia and Kerydin are the primary factors driving the market expansion in North America. According to a press release from Moberg Pharma AB, the market in North America will expand as a result of the approximately 5 million prescriptions that are written there each year for the treatment of onychomycosis.

Moreover, the demand for dermatophytic onychomycosis treatment is anticipated to rise in Europe as a result of the increased incidence of onychomycosis, attractive health reimbursement policies, and improved distribution of OTC pharmaceuticals through collaborations with retail pharmacies like Walmart, Walgreens, and others. According to a study that was published in the Journal of the European Academy of Dermatology and Venereology, onychomycosis is 4.3% prevalent in all of Europe. The European market is anticipated to be stimulated by this. However, because a few European nations, like Italy, Spain, Britain, etc., were among the hardest affected by the coronavirus pandemic, it is projected that the market would face a large decline in 2020.

The market in Asia Pacific is anticipated to increase dramatically as a result of the launch of new products, the rising prevalence of diabetes, and the rising geriatric population. According to Kaken Pharmaceuticals Co., Ltd., Jublia will be made accessible as a treatment for dermatophytic onychomycosis in Hong Kong beginning in March 2020. The Asia Pacific market is expected to be stimulated by this.

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.